Molecular Pathogenesis of Neuroendocrine Tumors: Implications for Current and Future Therapeutic Approaches
Kjell Öberg(Uppsala University Hospital), Bertram Wiedenmann(Charité - Universitätsmedizin Berlin), Laura H. Tang(Memorial Sloan Kettering Cancer Center), Mohid S. Khan(Sofia University), Philip A. Harris(Centre Hospitalier de l’Université de Montréal), Oriol Casanovas(Institut Català d'Oncologia), Justo P. Castaño(Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition), Patrice Denèfle(Sofia University), Daniel C. Chung(Massachusetts General Hospital), Aldo Scarpa(University of Verona), Gianfranco Delle Fave(CTO Andrea Alesini), Matthew H. Kulke(Moffitt Cancer Center)
Cited by 89
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
|Cancer Cell|2009|2.3k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k